Our recently published research on the characterization of vesicular stomatitis virus
(VSV) pathogenesis in swine, identified a systemic upregulation of interleukin 6 (IL-6)
during the acute phase of infection (Velazquez-Salinas et al., 2018). This upregulation
was observed during infection with a highly virulent VSV strain, suggesting a potential
association between IL-6 levels and virus virulence in pigs. In this opinion note
we would like to explore in more detail the biological functions of IL-6 in different
virus models, and present our perspective regarding the debatable role of IL-6 during
viral infections. While several studies show the essential role of IL-6 to mount a
proper immune response during some viral infections, others link this cytokine with
exacerbation of viral disease. These latter findings lend support to the hypothesis
that upregulation of IL-6 during certain viral infections may promote virus survival
and/or exacerbation of clinical disease.
IL-6 is a pleotropic cytokine produced in response to tissue damage and infections
(Tanaka et al., 2014). Multiple cell types including fibroblasts, keratinocytes, mesangial
cells, vascular endothelial cells, mast cells, macrophages, dendritic cells, and T
and B cells are associated with the production of this cytokine (Mauer et al., 2015).
After targeting its specific receptor, IL-6 starts a cascade of signaling events mainly
associated with the JAK/STAT3 activation pathway (Wang et al., 2013) promoting the
transcription of multiple downstream genes associated with cellular signaling processes,
including cytokines, receptors, adaptor proteins, and protein kinases (Pim-1, LDL-receptor,
GADD45 beta, SOCS1, MAP3K8, SOCS3, GLUT3, HB-EGF, ICAM1, Mx1, PTP4A3, SGK, Pim-2,
RHOBTB3, cAMP-GEFII, PDGF-receptor alpha, MLCK). It also controls the production of
proteins implicated in regulation of gene expression (Blimp1, id-2H, MAFF, TTP, C/EBP-beta,
SRY, TCF8, c-jun, junB, Bcl-3, Bcl-5, DEC1, Nmi, Stat1, eIF5, OBF-1, Oct-2, Stat3;
Brocke-Heidrich et al., 2004). The number of genes regulated by IL-6 activity may
explain the pleotropic nature of this interleukin. Accordingly, the biological consequences
of IL-6 production have been associated with both pro- and anti-inflammatory effects
(Scheller et al., 2011), highlighting IL-6's pivotal role in the activation and regulation
of the immune response. Biological activities affected by production of IL-6 include:
control of the differentiation of monocytes into macrophages by regulating the expression
of macrophage colony-stimulating factor (Chomarat et al., 2000), increasing B-cell
IgG production by regulating the expression of IL-21 (Yang et al., 2016), negative
regulation of dendritic cell maturation by activation of the STAT3 signaling pathway
(Park et al., 2004), as well as the promotion of the Th2 response by inhibiting Th1
polarization (Diehl and Rincon, 2002). Two different mechanisms have been described
to promote the inhibition of Th1 polarization by IL-6: (1) IL-6 stimulates CD4 T cells
to secrete IL-4 and direct the response to Th2, and (2) IL-6 affects the secretion
of IFNγ by CD4 T cells, an essential interferon to promote Th1 polarization. A similar
effect is produced in Th1 cells, where inhibition of IFNγ secretion in these cells
affects CD8 T cell activation (Dienz and Rincon, 2009; Green et al., 2013).
Moreover, in combination with the transforming growing factor beta, IL-6 induces the
differentiation of naïve CD4 into Th17 cells, which are important for the defense
against pathogens at mucosal sites (Guglani and Khader, 2010). Also, IL-6 synergic
interactions with IL-7 and IL-15 induce the differentiation and cytolytic capacity
of CD8 T cells (Cox et al., 2013). Importantly, IL-6 is a potent pyrogenic cytokine,
and has an essential role organizing lymphocyte trafficking to lymphoid organs during
febrile events (Evans et al., 2015).
In addition to its roles modulating the host immune response, IL-6 has been implicated
in the progression of several virus infectious. IL-6 is considered one of the most
important cytokines during an infection, along with interleukin 1 (IL-1) and tumor
necrosis factor alpha (TNF-a; Dienz and Rincon, 2009). Direct evidence supporting
the importance of IL-6 during viral infections has been gathered in experimental infections
using IL-6-deficient mice. Using this model, IL-6 has been shown to be essential for
survival of mice infected with influenza virus by promoting optimal regulation of
the T-cell response, inflammatory resolution, tissue remodeling promoting lung repair,
migration and phagocytic activities of macrophages, preventing viral-induced apoptosis
in lung epithelial cells, and regulation of IgG isotype switching (Lauder et al.,
2013; Yang et al., 2017). Other reports have also emphasized the importance of IL-6
during virus infections. Disruption of the IL-6 gene in mice infected with vaccinia
virus impaired the immune response by reducing the activity of specific cytotoxic
T-cells, while murine infection with VSV impaired the production of specific IgG antibodies
(Kopf et al., 1994). Additional evidence of IL-6's function during a virus infection
was observed during lymphocyte choriomeningitis virus infection of mice where IL-6
and/or IL-6R activity was blocked using specific monoclonal antibodies. In this model,
T helper and B-cell responses were reduced during the late stages of infection, negatively
affecting viral clearance (Harker et al., 2011).
Genetically engineered rabies virus carrying the IL-6 gene in its genomic backbone
has been used as an alternative model of experimentation to assess the relevance of
IL-6 during viral infections (Luo et al., 2018). Normal mice infected with this virus
showed a higher resistance to the viral infection compared with mice infected with
the parental virus. Animals infected with the engineered virus had an increased blood-brain
barrier permeability with a higher number of specific CD8-T and B-cells, increased
levels of circulating neutralizing antibodies, and an intensified innate immune response
in the brain as defined by up-regulation of multiple interferon-stimulated genes (ISG15,
ISG20, OAS1, OAS2, and MX2).
As a warning signal during viral infections, different immune cellular pathogen recognition
receptors, including toll-like receptors (TLR:2, 3, 4, 7, 8, and 9), nucleotide-binding
oligomerization domain-like receptors, DNA receptors, and retinoic acid-inducible
gene-1-like receptors, are able to sense a variety of pathogen-associated molecular
patterns displayed by viruses (envelope glycoproteins, single and double-stranded
RNA, and unmethylated CpG DNA), which stimulate transcription of IL-6 among other
proinflammatory cytokines (Kawai and Akira, 2010; Tanaka et al., 2014). In this context,
it has been shown that specific amino acid substitutions in a TLR-like structure in
the NS4B protein of a highly virulent classical swine fever virus (CSFV) strain resulted
in a completely attenuated phenotype in pigs. Infection of pigs with this mutant CSFV
was characterized by the sustained accumulation of IL-6 in tonsils. Further in vitro
experiments using exogenous IL-6 confirmed the ability of this cytokine to repress
the replication of CSFV in swine peripheral blood mononuclear cells, the natural target
cell during CSFV infection in pigs (Fernandez-Sainz et al., 2010).
Similarly, evidence of the antiviral effect of IL-6 was described during in vitro
studies conducted with hepatitis B virus (HBV) where the direct ability of exogenous
IL-6 to suppress the replication of this virus was described. Disruption of HBV replication
was characterized by a marked decrease in the number of viral genome-containing nucleocapsids,
an effect mediated in an interferon-independent manner (Kuo et al., 2009). Furthermore,
IL-6 was able to block HBV infection in hepatocytes by inhibiting expression of HBV
receptor in the human liver, i.e., the bile acid transporter Na (+)/taurocholate co-transporting
polypeptide (Bouezzedine et al., 2015), and effectively disrupted epigenetic control
of the nuclear cccDNA mini-chromosome, inhibiting HBV transcription (Palumbo et al.,
2015) and the expression of hepatocyte nuclear transcription factors 1 and 4 alpha
(Hosel et al., 2009).
However, experimental scientific evidence also suggests potential negative consequences
that increased levels of IL-6 might have on the cellular immune response against viruses.
In this context different potential mechanisms involving this cytokine might affect
viral clearance, ultimately favoring the establishment of a viral persistent state
in infected hosts.
First, in-vitro secretion of IL-6 by activated splenocytes, as a consequence of stimulation
of toll like receptor 1/2 by the agonist P3C, inhibited effector CD8 T-cell responses
by impairing the production of interferon gamma (IFN-γ) when compared with similarly
activated and stimulated splenocytes from IL-6−/− mice (Wu et al., 2015). Similar
results were obtained providing an exogenous source of IL-6, confirming the ability
of IL-6 to negatively regulate effector CD8 T-cell response after T cell activation.
This inhibition was orchestrated through the STAT3 signaling pathway producing the
upregulation of suppressor of cytokine signaling (SOCS3) that reduces the STAT4 phosphorylation
pathway induced by IL-12, which is essential for effector CD8-T cell differentiation
(Wu et al., 2015). Furthermore, in vivo blockage of IL-6 using a monoclonal antibody
during acute infection in mice with murine leukemia virus resulted in reduced viral
loads, and increased production of IFN-γ and the serine protease granzyme B (essential
to produce apoptosis in target cells; Wu et al., 2015).
Second, the synergistic interaction between IL-6 and interleukin 17 (IL-17) have been
associated with viral persistence and exacerbated clinical outcome during infection
with Theiler's murine encephalomyelitis virus (TMEV). Genetically engineered mice
carrying a human IL-6 transgene have excessive production of IL-6, leading to increased
production of Th17 cells during an immune response. The IL-6 and IL-17 synergistic
interaction leads to induction of anti-apoptotic molecules (Bcl-2 and Bcl-xL) inhibiting
the destruction of TMEV-infected cells by virus-specific CD8+ T-cells, therefore favoring
virus survival (Hou et al., 2014). Also, inhibition of apoptosis by IL-17 seems to
be associated with the ability of this cytokine to block the Fas-FasL pathway (Hou
et al., 2009). Interestingly, the induction of immunopathology, prevention of Th1
cells, and the inhibition of IL-2 and IFN-γ production have been mentioned as potential
detrimental factors induced by Th17 cells during viral infections caused by influenza
virus, Mouse hepatitis virus, hepatitis C virus, herpes simplex virus, and coxsackie
virus B3 (Martinez et al., 2012).
The last potential mechanism links IL-6 with the negative co-stimulator molecules
programmed cell death one (PD-1) and its ligand (PDL-1). Under normal conditions,
PD-1 and PDL-1 prevent autoimmunity by inducing T-cell regulation and maintaining
self-tolerance (Bardhan et al., 2016). However, during chronic viral infections, T-cell
ligation of PD-1 by PDL-1, expressed on infected cells, alters immunity against viruses
by preventing T-cell generation and expansion (Bardhan et al., 2016). Experimental
evidence evaluating the induction of PD-1 and PDL-1 after infection with TMEV in normal
and transgenic IL-6 mice showed that the excessive production of IL-6 displayed by
transgenic mice after infection positively correlates with increased up-regulation
of PD-1 and PDL-1 molecules in the central nervous system, and consequently with reduced
CD8+ cytolytic function (Jin et al., 2013). Interestingly, PD-1 and PDL-1 up-regulation
appeared to be the result of the cooperative action between IL-6 and interferon type
I, with IL-6 essential to the expression of maximum levels of PDL-1 (Jin et al., 2013).
Evidence from clinical studies in humans and animals have also linked the increased
systemic levels of IL-6 with the exacerbation of clinical outcomes involving viral
pathogens. In this context, increased levels of IL-6 in serum has been reported in
human patients chronically affected with Andes virus (Angulo et al., 2017), influenza
virus (Zheng et al., 2017), HBV (Torre et al., 1994), hepatitis C virus (Spanakis
et al., 2002), human immunodeficiency virus (HIV; Borges et al., 2015), Crimean-Congo
hemorrhagic fever virus (Ergonul et al., 2017), and Chikungunya virus (Chirathaworn
et al., 2013). Similar results have been reported in pigs and ponies infected with
VSV and influenza virus, respectively, where the virulence of different strains might
be positively correlated with both local and systemic detection of IL-6 (Wattrang
et al., 2003; Velazquez-Salinas et al., 2018). Additionally, transcriptome analysis
of persistently infected pharyngeal tissues collected from cattle with foot and mouth
disease virus showed a local increase of IL-6 expression (Pacheco et al., 2015), suggesting
that overexpression of IL-6 might be a possible mechanism favoring persistence of
some viruses. Similarly, in HIV-infected individuals increased levels of IL-6 positively
correlated with levels of residual viremia, while in ectocervical tissues, the presence
of IL-6 was correlated with enhanced transcriptional levels of HIV-1 (Rollenhagen
and Asin, 2011).
In conclusion, there is plentiful evidence supporting a significant role of IL-6 during
viral infections. However, certain scenarios create disparity of IL-6 production that
may be detrimental to the cellular immune response during viral infections. Two different
hypotheses may be considered to explain the change in IL-6 production during the immune
response to viral infection: (i) the increased ability of some viral strains to overcome
the immune response using a variety of evasion strategies (Beachboard and Horner,
2016), and consequently up-regulate the production of IL-6 as a result of increased
viral loads, and (ii) polymorphisms in the IL-6 gene promoter stimulating overexpression
of IL-6 during the immune response, a fact that has been shown to correlate with HBV
progression (Lan et al., 2015). This last hypothesis might explain clinical reports
correlating IL-6 overexpression with exacerbation of clinical outcomes in a sub-group
of individuals during an outbreak caused by a single virus strain. Interestingly,
this is consistent with experimental evidence in transgenic IL-6 mice (discussed below).
Experimental evidence supports the observation that overexpression of IL-6 during
the viral immune response might induce viral persistence by impairing the polarization
and functionality of Th1 cells and the lytic capacity of CD8 T-cells through different
mechanisms, leading to chronic infections (Figure 1). As a consequence of the constant
antigen stimulation, CD8 T-cells become unresponsive and fail to develop into memory
CD8 T-cells, a situation that limits viral clearance (Shin and Wherry, 2007; Bardhan
et al., 2016). Increased levels of IL-6 might also exacerbate the immunopathology
during chronic infections by increasing inflammation followed by cytokine secretion
and cellular recruitment as described during autoimmune diseases (Srirangan and Choy,
2010). In fact, this condition of increased inflammation may be an advantage for some
viruses by providing new cellular targets for subsequent viral infections (Pingen
et al., 2016).
Figure 1
Overexpression of IL-6 and its potential negative consequences on the viral immune
response. Current scientific evidence supports different scenarios where imbalance
on the IL-6 production after viral infection can affect viral clearance, promoting
viral persistence and chronic infections. (A) IL-6 might favor Th2 polarization by
stimulating STAT3 pathway, and consequently increasing the production of IL-4, and
the suppressor of cytokine signaling one protein (SOCS-1). SOCS-1 affects STAT 1 phosphorylation,
impairing IFNγ production by decreasing IFNγ self-loop stimulation. (B) IL-6 might
impair cytolysis by inducing the production of SOCS-3, affecting phosphorylation of
STAT 4, and consequently impairing IFNγ production, an essential IFN type II interferon
molecule to promote CD8 and NK cells activation. (C) IL-6 might promote infected cell
survival by inducing apoptosis. Overexpression of this cytokine increments Th17 polarization,
increasing IL-17 production in the cellular environment. IL-17 pathway induce the
production of the anti-apoptotic B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma extra-large
(Bcl-xL) proteins, which prevent mitochondrion to produce the cytochrome complex protein
(Cyt-c) after stimulation by the pro-apoptotic molecule protease Granzyme B, impairing
the production of active apoptotic caspase molecules. An additional scenario includes
the production of the programmed death ligand 1 protein (PD-L1) by the concerted action
of IFN type I and IL-6. Matching between PD-L1 and programed death protein 1 (PD-1)
switches off apoptosis mediated by CD8 T cells.
An interesting question arises regarding the potential of some viruses to selectively
up-regulate IL-6 levels as a possible immune evasion strategy. Although right now
there is no scientific evidence to support the causal relationship between IL-6 levels
and virulence, it could open new lines of research considering the capability of other
intracellular microorganisms, like Mycobacterium tuberculosis, to induce overexpression
of IL-6 to inhibit the autophagy process in infected cells (Dutta et al., 2012)
Further work is necessary to clarify the exact role of IL-6 during virus infections
and the potential role of this cytokine to be used as a biomarker of viral virulence.
Additional work exploring the potential therapeutic use of blocking IL-6 or different
products affected by its activity might provide insight into controlling persistent
viral infections. Caution is warranted for these kinds of studies, considering the
conflicting effects of this interleukin during the progression of different viral
infections. It is possible that the apparent contradictory function of IL-6 may depend
on diverse triggering events that can be directly linked to the characteristics inherent
to each virus infection. The pleiotropism of IL-6 function might stem from different
viral stimuli activating distinct patterns of effector host mechanisms and their corresponding
consequences.
Author Contributions
LV-S, AV-R, LR, and MB conceived, designed, and wrote this manuscript.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial
or financial relationships that could be construed as a potential conflict of interest.